Stereoselective Synthesis of an Omuralide Analogue Through a Lewis Acid Catalyzed Reaction of an Aldehyde and an Oxazole by Berman, Doris
Wellesley College
Wellesley College Digital Scholarship and Archive
Honors Thesis Collection
2014
Stereoselective Synthesis of an Omuralide
Analogue Through a Lewis Acid Catalyzed
Reaction of an Aldehyde and an Oxazole
Doris Berman
dberman@wellesley.edu
Follow this and additional works at: https://repository.wellesley.edu/thesiscollection
This Dissertation/Thesis is brought to you for free and open access by Wellesley College Digital Scholarship and Archive. It has been accepted for
inclusion in Honors Thesis Collection by an authorized administrator of Wellesley College Digital Scholarship and Archive. For more information,
please contact ir@wellesley.edu.
Recommended Citation
Berman, Doris, "Stereoselective Synthesis of an Omuralide Analogue Through a Lewis Acid Catalyzed Reaction of an Aldehyde and an




Stereoselective Synthesis of an Omuralide Analogue Through a Lewis Acid 




Dr. David R. Haines, Advisor 
 




A Thesis Submitted in Partial Fulfillment of the Requirement for the Bachelor of Arts 




	   1	  
Table of Contents 
Acknowledgements                  p. 2 
Abstract                   p. 3 
Biological Introduction                 p. 3-10 
Experimental Goals and Purpose                p. 10-15 
Results and Discussion                 p. 15-26 
Conclusion                   p. 27 
Experimental                   p. 27-36 
Appendix                   p. 36-46 








	   2	  
 
Acknowledgements 
 There are a lot of thank yous to be said, for my four years at Wellesley and two 
and a half years of working in the Haines lab.  First, thank you to Elizabeth Regan, whom 
I first shadowed when deciding whether I wanted to do organic chemistry research, and 
whose work ethic and research have been a major inspiration in my own thesis research.  
Thank you to all the other members of the Haines lab, past and present.  Thank you to the 
Ott Research group at T.U. Braunschweig, for letting me explore another aspect of 
organic chemistry research and making me feel welcome in Germany.  Thank you to 
Wellesley Cross Country and Track and Field, for being my family away from home and 
for all the long runs that keep me sane.  Thank you to my non-runner friends for sticking 
around when I disappear under mounds of schoolwork, and for pulling me out of it from 
time to time.  Thank you to my family for being the best cheering squad in existence.  
Thank you to my thesis committee, Professor Verschoor, who has the most amazing 
cookies and life advice; Professor Moyer, who has great comments and hard-hitting 
questions; and Professor Menkiti, who inspires me to be an ethical person and hopefully 
one day a good doctor.  A huge thank you to Flick Coleman, the ‘Gaussian guru’, for 
showing me some of the complexities of computational chemistry.  Finally, a huge thank 
you to Professor Haines, who has been the most amazing mentor, as he encouraged me to 
go abroad and to try new things at Wellesley.   I never expected to be a chemistry major, 
but with his support I have grown to love the subject, and am a better student, scientist, 








	   3	  
 
Abstract 
Lactacystin, or more specifically, its biologically active form, omuralide, is a 
known inhibitor of cell cycle progression in a number of cell lines.  However, omuralide 
is also an inhibitor of the proteasome, an essential protease within eukaryotic cells. 
Because of the complexity of the available syntheses, development of selective analogs 
of omuralide has progressed slowly.  Our research seeks to develop efficient and highly 
stereoselective syntheses of omuralide analogs via the metal catalyzed reaction of a chiral 
aldehyde with a protected oxazole.  This catalysis has been accomplished with high 
stereoselectivity using a simple aluminum catalyst but the efficiency of this reaction has 
not been high.  Results from a variety of additional catalysts will be discussed. 
 
Biological Introduction 
Chlamydia trachomatis is the cause of the most prevalent sexually transmitted 
disease in the United States: Chlamydia.  This obligate intracellular bacteria can infect 
both the urogenital tract and ocular epithelia.1 For females with urogenital tract 
infections, this can lead to a host of problems, including pelvic inflammatory diseases, 
ectopic pregnancy, and infertility.   Blindness often results from cases of ocular infection 
left untreated.  This is unfortunately still a frequent occurrence, particularly in 
impoverished areas of the world.   Chlamydia is currently the leading cause of 
preventable blindness worldwide.2 
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The pathogenic mechanism of C. trachomatis infection is still debated.  One 
explanation of the mechanism is that the infectious form of Chlamydia, called elementary 
bodies, attach and enter epithelial cells through the cellular membrane.  Once inside, they 
turn into replicative reticulate bodies, which create and reside in parasitic vacuoles inside 
the cell.  Reticulate bodies change back to elementary bodies and go on to infect other 
cells once they have released the necessary enzymes and proteins to control host cellular 
processes.  The number of elementary bodies produced is at a maximum two days post 
infection, however, many infections are asymptomatic for long periods of time past the 
two-day point.3  This, combined with the fact that one infected cell can produce several 
hundred new bacteria, are likely the reasons the disease is so persistent.  It remains 
unclear how exactly chlamydial organisms invade the epithelial cells they infect or how 
these organisms communicate with their host cells.7 
The Chlamydia bacteria secrete chlamydial protease/proteasome-like activity 
factor (CPAF), into eukaryotic host cells (fig. 1).9  Proteases are the major enzymes of 
protein degradation in the cytosol and nucleus, and CPAF performs this function.  It is, 
however, sometimes classified as a “proteasome-like activity factor” instead of a protease 
because its form and mechanism are different from many other proteases.  Once in the 
host cells, CPAF degrades several host transcription factors and proteins responsible for a 
range of cellular functions, including inflammation and DNA damage control.10 
Introducing CPAF to uninfected human cells replicates many of the symptoms of the 
disease, implicating it as a major factor in the generation of infection symptoms.12   
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Figure 1:  Proposed mechanism of CPAF function.  If CPAF is inhibited with an anti-
CPAF peptide, as shown on the right of this figure, the parasitic vacuole/inclusion 
becomes unstable and breaks down (Jorgensen et al., 2011)8. 
 
CPAF is a serine protease, one of a very common class of peptide cleaving 
molecules that use the amino acid serine as part of a catalytic triad to catalyze 
the breakage of the N-C bond in proteins (fig. 2).  CPAF displays resistance to the often-
used serine protease inhibitors N-p-Tosyl-L-phenylalanine chloromethyl ketone (TPCK) 
and phenylmethanesulfonyl fluoride (PMSF), however.  This is likely because these 
drugs have large hydrophilic moieties unlike lactacystin, a molecule that displays potent 
anti-CPAF properties and has large hydrophobic portions.   Because of its potency as an 
inhibitor of CPAF, it has been used to elucidate its X-ray crystallography structure (fig. 
3).13   
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Figure 2: Catalytic properties of CPAF. A. The figure on the top left shows a crystal 
structure model of CPAF.  Structural information such as this helps to confirm that CPAF 
is a Serine protease, as S499 is in the center of the catalytic site.  Two CPAF molecules 
(in pink and blue) form an asymmetric unit.  B. The catalytic triad of CPAF: S499, H105, 
and E558  (Adapted from Huang et. al., 2008).13  C. The bottom figure shows the 
mechanism of another serine protease, chymotrypsin, which is believed to be very similar 
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Figure 3: Ribbon diagram of lactacystin inhibition in CPAF.  Protein parameters 
processed from RCSB protein data bank (3DPM).  Protein chains are colored from N 
terminal to C terminal using a rainbow color gradient (Red to Violet).   
 
Individuals do not develop immunity to chlamydia once the infection is 
cleared.   A person could easily be affected multiple times.  Antimicrobial resistance is a 
growing problem, for Chlamydia as well as a host of other microbial diseases.3   
Although viable antibiotics against Chlamydia already exist, it is still necessary to 
synthesize novel antibiotics in case traditional methods lose their efficacy.  While there 
are few cases of antibiotic-resistant chlamydia so far, chlamydia easily develops 
antibiotic resistance in in-vitro studies.4  Already, HeLa cells infected with Chlamydia 
show no decrease in viability of the Chlamydia bacteria when treated with traditional 
antibiotics.  The underlying mechanisms for this resistance are still unclear.5 Other 
sexually transmitted diseases have already developed antibiotic resistance.  For example, 
Gonorrhea has such widespread immunity to the traditional treatment fluoroquinolone 
that a newer drug, cephalosporin is now preferentially prescribed.6 It is important to find 
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other options for treatment.  One molecule that has been the focus of a substantial amount 
of research is lactacystin (fig. 4).    
 
Figure 4: (+)-Lactacystin and omuralide 
Much research has been done to discover a way of chemically inhibiting bacterial 
CPAF.  Probable active sites of CPAF have been identified, and lactacystin, or more 
specifically, its active form, the β-lactone–γ-lactam omuralide, has shown much 
promise.  Lactacystin is a natural microbial product that was isolated in 1991.  Further 
studies showed that lactacystin inhibits the 20S proteasome in mammalian and bacterial 
cells (fig. 5).7   Lactacystin is converted to omuralide spontaneously in the extracellular 
medium.  While lactacystin is incapable of crossing the cell membrane, omuralide can 
enter the cell unaided and inhibit the proteasome.8 
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Figure 5: This is a topological model of the 20S proteasome in yeast.  The 20S 
proteasome has been found to have similar structures in yeast, bacteria, and mammalian 
cells.  This figure shows the surface structure of the 28 subunits of this proteasome. The 
proteasome has two entry points, through which substrates can enter and the product can 
be released  (Figure from Groll et al. 1997). 
 
Omuralide shows promise in the treatment of several diseases other than 
chlamydia.  Recent research has shown that targeting the proteasome in cancer cells with 
molecules such as omuralide leads to apoptosis of the cancerous cells.  Omuralide is now 
being proposed as a treatment for cancer, malaria, and a host of other diseases, as well as 
chlamydia, which are controlled by inhibition of the 20S proteasome.9  
While omuralide has been proposed as an antibiotic, it also affects the host cell 
proteasome, so synthesis of a similar molecule that does not affect the host cell but still 
inhibits bacterial CPAF is required.  One proposed molecule is a phenyl-omuralide 
analogue in which the isopropyl functional group is replaced by a benzene ring.  It has 
been shown that this analogue does not inhibit the host cell proteasome, most 
prominently in a paper by Corey and Li, in which they tested over twenty analogues of 
	   10	  
omuralide, and showed that only two, the phenyl analogue and a ketone analogue, 
showed no inhibition of the bovine 20S proteasome.  The effect of these analogues on 
CPAF is still unknown as the amount synthesized was not sufficient for further biological 
testing.10  An important goal is therefore to test the efficacy of these compounds in 
inhibiting the chlamydial protease.  The Haines lab is working to synthesize an adequate 
amount of this analogue to evaluate its effectiveness in cellular and animal models of 
chlamydial infection.  
 
Experimental Goals and Purpose 
The synthesis of omuralide has been undertaken by several research groups.  The 
Haines lab has been working on the synthesis of a phenyl-omuralide analogue with four 
specific chiral centers (fig. 6).  This synthesis is modified from the procedure published 
by Soucy11 and is three steps shorter than the initial synthesis by E.J. Corey.10, 13, 14   This 
synthetic scheme is particularly useful because it allows for substitution of various 
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This paper is primarily concerned with improving the reaction between 5-
methoxy-2-pmethoxyphenyloxazole with N, N-Diethyl-2-(R)-methyl-3- 
oxopropionamide in the presence of a Lewis acid catalyst (figure 6).  Once the oxazole 
(compound 3 of fig. 8) and the aldehyde (compound 6 of fig. 7) intermediates are created, 
they are joined through a diastereoselective aldol reaction, setting up the required 
chirality of the chiral carbons for the rest of the synthesis.  Both the requisite aldehyde, 
N, N-Diethyl-2-(R)-methyl-3-oxopropionamide, and oxazole, 5-methoxy-2-
methoxyphenyloxazole, were created, and their synthesis is described in the following 
sections.   
 
Figure 7: Synthesis of N,N-Diethyl-2-(R)-methyl-3-oxopropionamide. 
The aldehyde (compound 6 of figure 7) is noteworthy in its one chiral center.  We 
see that nucleophilic attack is most likely to occur at the terminal carbonyl that has the 
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Figure 8: Synthesis of 5-methoxy-2-methoxyphenyloxazole.   
From examining the resonance in 5-methoxy-2-methoxyphenyloxazole, it can be 
seen that the secondary carbon adjacent to the nitrogen has the most nucleophilicity due 
to the electron-donating methoxy groups on each end of the oxazole.  This is the carbon 
that acts as the nucleophile in the complexation reaction between the oxazole and 
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 In another synthesis published by Francois Soucy’s research group, the trivalent 
Lewis acid dimethyl aluminum chloride was used to catalyze the reaction between the 
aldehyde and a deprotonated oxazoline.  This Lewis acid complexes to the aliphatic 
aldehyde and oxazoline, holding them in place and giving a new complex with specific 
chirality.  This is an example of controlling stereochemistry, but not the activation needed 
since a deprotonated nucleophile is already sufficiently activated by deprotonation by a 
strong base.  Dr. David Evans’ research group also used an aluminum-based catalyst 
(shown below in fig. 10) to add benzaldehyde to the oxazole, but this reactivity was 
restricted to aromatic aldehydes.15 
 
Figure 10: The complex binapthyl aluminum catalyst, (R)-2,2'-bis(3,5-Di-tert-butyl-2-
hydroxybenzylideneamino)-1,1'-binaphthyl aluminum chloride synthesized by Evans et 
al.15 The red line represents a covalent bond between the two carbons it connects.  The 
catalyst is activated by loss of the chloride upon addition of AgSbF6. 
 
 The Haines lab has also had some success with the dimethyl aluminum chloride 
catalyst in a reaction between 5-methoxy-2-methoxyphenyloxazole and N, N-Diethyl-2-
(R)-methyl-3-oxopropionamide.   The yield of this reaction was only twenty percent, 
however.  This reaction combines the work of Soucy and Evans in a new reaction where 
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one stereoisomer was isolated, and we can assume it was the desired stereoisomer since 
the attack by the oxazole is favored from the less sterically hindered direction.    
 Dimethyl aluminum chloride is unfortunately particularly flammable when in the 
presence of oxygen, and even when working in a nitrogen environment, it often ignites in 
the syringe transition from the storage container (which is under nitrogen) to the reaction 
vessel (which is also under nitrogen).  It also produces product in low yield in part due to 
the methyl’s ability to act as a nucleophile instead of the oxazole.  It is important 
therefore to find a more stable and less nucleophilic catalyst that is still capable of 
complexation to both carbonyls of our aldehyde.  Such a catalyst makes the carbon of the 
aldehyde that bonds to the oxazole more electrophilic.  This catalyst should also move the 
two carbonyls on the aldehyde into the correct spatial parameters for addition to the 
oxazole.  
This thesis contains some of the attempts to find another Lewis acid catalyst that 
will activate aldehydes with no benzyl substituent.  From previous studies conducted by 
the Haines lab and other groups, we have narrowed our approach to Lewis acid catalysts 
containing three metals: aluminum, zinc, and copper.16  This paper describes experiments 
with several simple catalysts.  Those tested so far are zinc chloride, dimethyl aluminum 
chloride, and diethyl aluminum chloride.  
 Finally, the molecules of interest (shown in fig. 11) were created with Gaussview, 
and several semi-empirical and Hartree-Fock calculations were run on the complexation 
reactions.  The goal was to accurately model the effect of the dimethyl aluminum 
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chloride catalyst and to elucidate which enantiomer is formed during the complexation 
reaction.  The results for these calculations are presented in this paper as well. 
 
 
Figure 11: Molecular models of 5-methoxy-2-pmethoxyphenyloxazole (left) and N, N-
Diethyl-2-(R)-methyl-3-oxopropionamide (right) created in Gaussview. 
 
 
Results and Discussion 
Total synthesis of aldehyde, N,N-Diethyl-2-(R)-methyl-3-oxopropionamide 
 First, methyl 2(R)-3-hydroxy-2-methylpropionate was reacted with benzyl 2,2,2-
trichloroacetimidate in a nucleophilic substitution reaction.  Triflic acid, CF3SO3H, is a 
very strong acid that protonates the nitrogen on the methylpropionate, making it a better 
leaving group, promoting attack at the benzylic carbon and the leaving of the entire 
amide functional group (see Fig. 12). 
 




Figure 12: Mechanism of N,N-Diethyl-2-(R)-methyl-3-oxopropionamide formation. 
 In the next step of the synthesis, lithium hydroxide is used as a strong nucleophile.  
The hydroxyl attacks the carbon at the C=O double bond in a base catalyzed ester 
hydrolysis (fig. 13).   
   
Figure 13: Mechanism for the synthesis of (2R)-3-Benzyloxy-2-methylpropionic acid. 
 According to the original synthesis, the next step uses the peptide coupling 
reagent  N,N,N′,N′-Tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate	  
 (TBTU) and diisopropylethylamine, but this synthesis was modified to use 
hydroxybenzotriazole (HOBT) and 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC), which used in conjunction, activate the carboxyl and promote the formation of 
amide bonds.17  EDC acts as the first electrophile/leaving group, and then HOBT replaces 
the EDC since it is a better electrophile than EDC.  The basic diethyl amine is in excess, 
so it deprotonates the carboxylic acid, but will only add once there is a good leaving 
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Figure 14: Mechanism for the synthesis of 3-Benzyloxy-N,N-diethyl-2-(R)-
methylpropionamide. 
 
 Next, a catalytic hydrogenation reaction was performed.  In the presence of a 
metal catalyst (in this case Pd(OH)2 on carbon), the hydrogen-hydrogen bond breaks and 
each hydrogen attaches to the surface of the metal catalyst.  The aromatic benzene is also 
drawn to the surface of the metal catalyst, and hydrogens are transferred from the metal 
surface to the oxygen and benzylic carbon, breaking the bond between them.  The 
benzylic bond is the weakest, so even if the hydrogen complexes to the pi bonds in the 
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Figure 15: Hydrogenolysis of N,N-Diethyl-3-hydroxy-2-(R)-methylpropionamide. 
 In the final step of the synthesis, Dess-Martin periodinane, a highly sensitive and 
expensive catalyst that selectively oxidizes alcohols to aldehydes or ketones, and 
minimizes the possibility of further oxidation to carboxylic acids, is used.  This creates 
the final product, N,N-Diethyl-2-(R)-methyl-3-oxopropionamide.  The hydroxyl oxygen 
attacks the iodine (either in an SN1 or SN2 type mechanism), pushing off an acetate 
leaving group.  Then, through internal attack by the carbonyl oxygen and subsequent 
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Figure 16: Mechanism of the Dess-Martin Oxidation reaction.   
 
Synthesis of 5-methoxy-2-methoxyphenlyoxazole. 
In the first step of this synthesis, glycine methyl ester hydrochloride was reacted 
with methoxybenzoyl chloride in the presence of the basic triethyl amine.  This resulted 
in a simple substitution reaction, with the nucleophilic nitrogen attacking at the carbonyl 







Figure 17: Mechanism of formation of N-4-methoxybenzoylglycine methyl ester. 
 
Phosphorus pentoxide, which is a dehydrating agent, bonds to the most negative 
oxygen of the amide carbonyl, making the oxygen a good leaving group, and then 
through elimination, the oxygen carbon bond forms and the oxygen-phosphorous 
compound leaves, completing the favorable five-membered ring and forming 5-methoxy-






















Figure 18: Mechanism of ring closure reaction in the formation of 5-methoxy-2-p-
methoxyphenyloxazole. 
 
Reaction of 5-methoxy-2-pmethoxyphenyloxazole with N, N-diethyl-2-(R)-methyl-3-
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In the first attempt at this reaction, the predominant product was identified as a 
hydrolyzed byproduct.  Once water was added, the zinc chloride could act as a Lewis 
acid, and the zinc could complex to nitrogen.  Then, the hydrogen adds to the nitrogen 
and the hydroxyl group adds to the carbon.  The potential hydrolyzed product is shown in 
the figure below (fig. 19).  
 
 
Figure 19: Proposed by-product of oxazole synthesis due to presence of water. 
 
When the reaction was run the second time, proton NMR was taken of the impure 
mixture, and key new peaks in the range of 5-6 ppm were observed.  This is good 
primary evidence of some complexation reaction occurring (Fig. 20).  However, the 
separation of the reaction mixture was not a success, and no products were isolated.  
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Reaction of 5-methoxy-2-pmethoxyphenyloxazole with N, N-Diethyl-2-(R)-methyl-3-
oxopropionamide in the presence of a diethyl aluminum chloride catalyst 
In this reaction, diethyl aluminum chloride, which acts as a Lewis acid, will attack 
the carbonyl of the aldehyde and the carbonyl of the amide, holding them in place and 
withdrawing electron density.  This makes the carbon susceptible to nucleophilic attack 
by the carbon on the oxazole that is most negative because of resonance.  The oxazole is 
nucleophilic because of the electron donating methoxy groups, and it attacks at the less 
sterically hindered carbonyl carbon.  An NMR peak indicative of an aldehyde/oxazole 
product in low yield was isolated (appendix 11), as well as a peak indicative of an 
aldehyde/hydrolyzed oxazole product (appendix 12).   
 Figure 21: Complexation reaction as catalyzed by dimethyl aluminum chloride. 
Use of the ketone N,N-Diethylacetoacetamide as an aldehyde substitute: 
Because the yield of the aldehyde synthesis reaction was so low, the dimethyl 
aluminum chloride reaction was also attempted with the commercially available N,N-
Diethylacetoacetamide (Fig. 22) instead of the original aldehyde.  While the central 
carbon is no longer chiral, and the carbonyl at which an attack would occur is more 
sterically hindered, it is still a good primary test of whether activation of the oxygens 
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was attempted with a dimethylaluminum chloride catalyst because it had already been 
proven effective with the original reactants.  Although peaks with oxazole were separated 
(Appendix 9 and 10), the purification was likely incomplete, as no peaks containing an 
oxazole-ketone complex or any ketone were isolated.  This compound warrants further 
exploration, as, although it is an imperfect match, it could be an inexpensive model 
compound to substitute for a very difficult compound to synthesize.   
  
Figure 22: Structure of N,N-Diethylacetoacetamide. 
Gaussian calculations: 
 We wished to model the complexation reaction of dimethyl aluminum to aldehyde 
and the attack from the oxazole to the aldehyde to have further evidence of which 
stereochemistry is favored in the final product.  Using two models in Gaussian, semi-
empirical and Hartree-Fock, attempts to quantify these reactions were made.  In the first 
simulation (fig. 23), the dimethyl aluminum chloridecatalyst can be seen complexing to 
the two oxygens of the aldehyde, twisting the conformation of the carbons to bring the 
oxygens from a staggered orentation to an orientation in which the two oxygens are in 
line with each other.  This supports the claim that the dimethyl aluminum chloride 
catalyst affects the orientation of the oxygens.  An optimization was run twice, first with 
semi-empirical parameters, which are quicker but make more assumptions, and then with 
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Hartree-Fock parameters, which take hours but are more accurate.  Post-optimization, it 
could be seen that the oxygens lie parallel to each other. Additionally, before the addition 
of a catalyst, the O=C-C bond angle (indicated with an orange arrow in figure 23) was 
121.107o, and after the addition of the catalyst it was 126.737o.  
 
Figure 23: Semi-empirical optimization of catalytic activation using Gaussview. N, 
N-Diethyl-2-(R)-methyl-3-oxopropionamide is shown complexed with the dimethyl 
aluminum cation.  The left-hand image is from before the complexation to the catalyst.  
The right hand image is complexation.  Both molecules were optimized using semi-
empirical methods. 
 
 When it was attempted to see whether dimethyl aluminum cation catalyst 
remained complexed to the aldehyde after the attack by the oxazole, the compounds were 
so large that Gaussian kept delivering error reports instead of final calculations.  Further 
attempts should be made to quantify this reaction. 
Future Research Goals: 
The aldehyde used in this reaction has a short lifespan.  The compound must be 
stringently maintained free of oxygen and water, as a problem in the past has been 
hydrolyzed byproducts.  As such, the synthesis must be repeated frequently.  It would be 
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useful to continue testing Lewis acid catalysts in the reaction between the aldehyde and 
the oxazole, but first, more aldehyde must be synthesized.   
Further tests should be run on diethyl aluminum chloride to confirm initial results 
as well.  We could modify the experimental procedure by using pure diethyl aluminum 
chloride instead of the diethyl aluminum chloride in hexane solution that was used for 
this reaction.  Although the pure diethyl aluminum chloride compound still poses the 
flammability problem, it would be useful to try to see whether the solvent affects the 
reaction.  If an attempt with pure diethyl aluminum chloride promotes higher yield, that 
would confirm our hypothesis that diethyl aluminum chloride acts as a weaker 
nucleophile. 
Copper II catalysts are also potentially useful.  A study by Evans et al. showed 
that CuII-bis (oxazoline) complexes show similar efficacy rates as the complex aluminum 
catalyst discussed above in similar reactions between oxazoles and aldehydes, to 
stereoselectivity of up to 95%.  Such catalysts display the same bidentate complexation 
the reaction studied in this paper requires.  The same paper also confirms the use of 
toluene as a solvent, as poorly coordinating solvents promote the highest rate of catalyst 
turnover.23 
Once the optimal catalyst is selected, six more steps remain in the total synthesis.  
At this point, (molecule 2 of fig. 13), there are three chiral centers, two of which have the 
final desired chirality.  The third has the right stereochemistry as well, but is directly 
controlled later in the synthesis.  The omuralide analogue has four total desired chiral 
centers, the remaining two controlled by the two chiral centers that are already set. 











Figure 24: Proposed complete synthesis of phenyl omuralide analogue, starting from the 
addition of aldehyde to oxazole. The bottom figures highlight the four desired chiral 
centers in the final omuralide molecule and the two desired chiral centers that exist at 
step two of the total synthesis. 
 
Conclusion 
 With the conclusion of this work, we have seen that all attempts to react the 
aldehyde and oxazole in the presence of zinc chloride have so far been unsuccessful, and 
it should likely be abandoned as a potential catalyst.  Diethyl aluminum chloride, 
however, still bears promise, and further tests should be conducted with this catalyst.  
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Further tests also need to be run on our ketone substitute, as it still has promise as an 
inexpensive model for the aldehyde.  Hopefully we can test copper complexes at some 
point as well.  Six more steps need to be achieved for total synthesis.   
 
Experimental 
All reagents were acquired from Sigma-Aldrich and used without further 
purification.  All glassware and stir bars were dried overnight in an oven.  Mass spectra 
were measured with an Agilent 6890N Network GC System coupled with an electron 
impact Agilent 5937 Network Mass Selective Detector.  The method "RAYANNE" 
(Tinitial=325oC, rate = 20oC/sec; split mode (inlet); mobile phase = He(g); constant flow 
mode, flow rate 1.0 mL/min; injection volume 1.0 µL, pressure 11.6 psi) was used for 
GC/MS analysis.  1HNMR and 13CNMR spectra were recorded using Bruker 300 MHz 
WIN-NMR spectrometer with TMS as a standard.  Flash chromatography was performed 
using Biotage gradient flash purification and gravity columns were prepared using silica 
gel from Sigma Aldrich, 70-230 mesh, 60 Å, with the slurry method of column 
preparation.  Catalytic hydrogenation was performed with Parr Instrument Company 
Reaction Apparatus.   
 
Preparation of Methyl 2(R)-3-benzyl-2-methylpropionate.   






Methyl (2R)-3-hydroxy-2-methylpropionate (5.16 g, 43.8 mmol) was dissolved in 
100 mL of cyclohexane and 50 mL of dichloromethane.  Benzyl 2,2,2-trichloro 
acetimidate (13.54g, 53.7 mmol) was added to the reaction mixture, followed by adding 
triflic acid (0.4 mL, 4.6 mmol) slowly to the reaction mixture.  The reaction was stirred at 
room temperature for 24 hours.  The suspension was then vacuum filtered and the filtrant 
washed well with dichloromethane.  The filtrant was then added to the original 
filtrate.  Solvents were washed with water (2x100mL), saturated sodium hydrogen 
carbonate (2x50 mL), and brine (2x25mL).  The organic fraction was separated with a 
separatory funnel and placed in an Erlenmeyer flask, then dried over magnesium 
sulfate.  The solution was filtered to remove MgSO4, and solvent was 
evaporated.  GC/MS of unpurified reaction showed a peak with m/z of 208 at a retention 
time of 7.759 minutes, similar to previous experiments (Appendix 1). 
To isolate the desired product, a silica gravity column was run.  All products were 
dissolved in 5 mL of hexanes and added to the column, and the glassware was washed 
two more times with 5mL of hexanes.  The column was run at 0-15% EtOH in hexanes, 
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were drawn for a total of 23 fractions.  The purified compound was 90% pure as 
determined by GC/MS (Appendix 2).  The remaining solvent was evaporated using a 
rotovap, yielding 6.315 g of slightly yellow liquid (percent yield: 57%).  
 
Preparation of 2(R)-3-Benzyloxy-2-methylpropionic acid 
 
Methyl (2R)-3-benzyl-2-methylpropionate (6.34 g, 44.94 mmol) was added to 100 
mL of a 1:1 mixture of THF and water, and the mixture was cooled on ice.  To this cold 
mixture, LiOH (1.096 g, 45.7 mmol) was added in small portions over 10 minutes, and 
the reaction was stirred at 4oC.  After 24 hours left stirring at 4oC, NaHCO3 (3.769 g, 44.9 
mmol) and water (16mL) were added and most of the THF was removed under 
vacuum.  The aqueous solution was washed with dichloromethane (4x20 mL) and 
acidified to pH 1 with 6 M HCl.  The pH was tested with pH paper, and a yellow organic 
layer quickly formed.  The acidified suspension was extracted with dichloromethane 
(3x40 mL).  The organic fraction was dried over sodium sulfate, and the solvent was 
evaporated under vacuum to give 2.1 g of a nearly pure product, which was a slightly 
yellow oil (2.1g, 10.8 mmol, 24% yield).  1H NMR (appendix 3) (CDCl3) * 9.95 (1H, OH) 
7.5 (s, 5H, Ph), 4.6 (s, 2H, benzylic), 3.8 (d, 2H, propionyl CH2), 2.9 (s, 1H, propionyl 
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Preparation of 3-Benzyloxy-N,-NDiethyl-2-(R)-methyl propionamide 
 
     3-Benzyloxy-N,-N Diethyl-2-(R)-methyl propionamide (2.1 g, 10.8 mmol) was 
dissolved in low water CH3CN (12.57 mL), and the solution was cooled on ice for 15 
minutes.  Diethylamine (1.32 mL, 2.30 g, 31.4 mmol), Hydroxybenzotriazole (HOBT, 
1.67g, 10.9 mmol) and Ethyl-3-(3-dimethyaminopropyl)carbodiimide (EDC, 1.70g, 10.9 
mmol) were added to the solution.  The reaction was stirred on ice for two hours.  Ether 
(14.2 mL) and water (57 mL) were added to the reaction and ether was collected.  The 
aqueous layer was extracted with additional ether (2x14.2 mL).  The combined organic 
layers were washed with 5% HCl (2x5mL) and then saturated NaHCO3 (10mL).  The 
organic layer was dried with Na2SO4, and the solvent was evaporated, leaving 5.05g of 
product as a deep yellow oil.   
To purify the resulting mixture, a 125 mL gravity column in a 1:1 mixture of 
EtOAc and hexanes was run.   Fractions of 25 mL were collected for 375 mL total.  After 
separation, 0.45 g of 3-Benzyloxy-N,-NDiethyl-2-(R)-methyl propionamide remained, as 
a very light yellow oil (1.8mmol, percent yield, 10%).  1H NMR (appendix 4) (CDCl3), 
7.3 (5H, Ph), 4.5 (m, 2H, benzyl CH2), 4.3 (d, 2H, propionyl CH2), 4.0 (s,1H, propionyl 
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Preparation of N,N-Diethyl-3-hydroxy-2(R)-methyl propionamide. 
 
3-Benzyloxy-N,-NDiethyl-2-(R)-methyl propionamide (4.85g, 19.4mmol) was 
dissolved in 33 mL of CH3OH.  Palladium hydroxide (20% on C, 0.37g) was added to a 
reaction flask, and the flask was connected to the hydrogenator.  The reaction was placed 
under H2 (10 PSI).  After 48 hours the reaction mixture was gravity filtered and the 
solvent was evaporated. 1H NMR (appendix 5) (CDCl3) * 4.5 (s, 3H, OH hydrogen and 
propynyl CH2), 3.5 (m, 4H, ethyl CH2), 3.0 (s, methine CH), 1.3 (m, 9H, methyl CH3’s). 
Preparation of N,N-Diethyl-2-(R)-methyl-3-oxopropionamide. 
 
Wet CH2Cl2 was prepared by stirring 50 mL of CH2Cl2 with 2 mL of water for 48 
hours. N,N-Diethyl-3-hydroxy-2-(R)-methylpropionamide (0.41 g, 2.59 mmol) was 
dissolved in the mixture.  Dess-Martin periodinane (1.8 g) was added slowly over 8 
minutes.  The reaction mixture was stirred at room temperature for 1 hour.  The reaction 
was cooled in an ice bath and quenched by the addition of a -4oC solution of Na2S2O3 
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ice for 10 minutes, ether (50 mL) was added, and the mixture was stirred vigorously at 
RT for an additional 10 minutes.  The organic layer was collected and the aqueous layer 
was washed with 1:2 CH2Cl2: ether (2x20mL).  Organic layers were washed with brine 
(2x25mL) then dried over Na2SO4.  The solvent was evaporated and the impure aldehyde 
was stored as a solution in CH2Cl2 under nitrogen at 0oC.  1H NMR (appendix 7) (CDCl3) 
* 9.7 (1H, aldehyde H), 3-4, (m 5H, ethyl CH2’s and CH), 1-1.5 (15H, M, propionyl 
CH3a, ethyl CH3s). 






N-4-Methoxybenzoylglycene methyl ester (34.23 g) was dissolved in 310 mL of 
chloroform.  To get rid of water, 100 mL chloroform was evaporated off with a 
rotovap.   Phosphorus pentoxide (95g) was added, and the reaction mixture was heated to 
reflux.  Solids formed as the reaction progressed, inhibiting the stir bar.  These solids 
were broken up over the course of the reaction.  After 41 hours, the reaction was removed 
from heat and placed on ice.  When the reaction mixture was sufficiently cool, it was 
poured into a 2.6 molar solution of sodium hydroxide (89.71g in 900mL water).  This 
was also kept on ice.   
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The mixture was poured into a separatory funnel, and the aqueous and organic 
layers were separated. The organic layer was placed in a freezer overnight, and crystals 
formed.  The organic layer was vacuum filtered, and the solids were collected on filter 
paper. GC/MS in dichloromethane showed two main peaks, one 49% of the product, with 
an m/z of 166 and the other 41% of the product with an m/z of 205 (appendix 1).  The 
solvent was evaporated, and then hexanes were added to the mixture.  The mixture 
dissolved only partially in hexanes, so another GC/MS was run of the liquid, and it was 
found that the suspected byproduct was much more soluble in hexanes than the suspected 
oxazole.  The solid that did not dissolve was filtered through vacuum filtration.  The solid 
was then washed with 20% ethyl acetate in hexanes.  GC/MS showed that our product 
was pure and had an m/z of 205 (appendix 2).    
 
Reaction of 5-methoxy-2-pmethoxyphenyloxazole with N, N-Diethyl-2-(R)-methyl-3-
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Since there was a very limited amount of aldehyde left over from earlier 
experimentation, the first test was run on a very small scale.  From previous 
experimentation, it was likely that since it had been left in a freezer for several months, it 
would be decarboxylated.  However, ‘HNMR of the product showed that our product was 
still an aldehyde.  A 1:1 molar ratio of aldehyde to oxazole was used (0.03 g of aldehyde 
with 0.04 g of oxazole) in 3 mL of a 1 molar solution of zinc chloride in diethyl 
ether.  The reaction was run under nitrogen to eliminate the presence of oxygen as much 
as possible.   The reaction was first stirred on ice and then warmed to room 
temperature.  After 48 hours, water was added to the solution and the solution poured into 
a separatory funnel.  The organic layer was separated, the solvent was evaporated, and an 
‘HNMR was taken of the remaining solid.   
The HNMR unfortunately showed many peaks indicative of oxazole as the 
primary compound present.  Flash chromatography was used to separate the products, 
and the column was run from 24-80% ethyl acetate in hexanes.  Four peaks were 
separated.  The first peak was identified as recovered aldehyde, the second and largest 
peak was identified as oxazole (appendix 15), and the third and fourth peaks did not come 
off of the column until it was run at 80% ethyl acetate in hexanes for several column 
volumes. These third and fourth peaks were identified through HNMR as likely 
hydrolyzed byproducts of the oxazole, due to the water that was present during the 
reaction (appendix 14).    
The second time this reaction was run, a 1:1 mixture of zinc chloride to aldehyde 
was dissolved in anhydrous toluene, and then the mixture was placed on a rotovap where 
a third of the solvent was evaporated.  This was in an attempt to get rid of most of the 
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diethyl ether to get better activation of the product.  The zinc chloride in the first reaction 
likely remained complexed to the diethyl ether instead of to the aldehyde, which is why 
we did not get a high product yield.  The hope was that by evaporating off most of the 
diethyl ether, we could displace the remaining ether with aldehyde.  The reaction was 
once again performed under a nitrogen line.  Interestingly, this time there were bubbles 
when the zinc chloride was added to the aldehyde.  The mixture was cooled on dry ice, 
and oxazole was added.  The mixture was left to stir for 48 hours and let warm to room 
temperature.  TLC in 40% ethyl acetate and hexanes showed four distinct spots and 
product left at origin.  NMR of crude product (Appendix 15) showed key new peaks in 
the range of 5-6 ppm.  HPLC was performed, using a 25-40% ethyl acetate in hexanes 
solution, but only two peaks were observed during the separation.  It might be useful to 
conduct this experiment again, since the two most interesting spots were lost during 
column chromatography, however the control oxazole spot (TLC was run with mixture 
spot and pure oxazole spot) was the largest, so it is likely that most of the product 
remained starting material.  
 
Reaction of oxazole with aldehyde in the presence of a diethyl aluminum chloride 
catalyst. 
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5-Methoxy-2-pmethoxyphenyloxazole (0.0474 g, 0.21 mmol) was dissolved in 
toluene (2.5 mL).  N, N-Diethyl-2-(R)-methyl-3-oxopropionamide (0.1199 g, 0.21 mmol) 
was dissolved in toluene (2.5 mL) as well.  The aldehyde solution was placed under a 
nitrogen line for 3 hours, in an -84oC bath of ethyl acetate (cooling first with dry ice and 
then with liquid nitrogen_.  Then approximately 1mL of diethyl aluminum chloride was 
added to the reaction mixture.  This mixture was stirred for 10 minutes, and then the 
oxazole was added.  Reaction agitation was stopped after 48 hours, and the reaction was 
refrigerated.  TLC of the mixture with oxazole as a control showed an extra spot that we 
hypothesized was the desired product.   
To separate the compounds present, purification was done using flash 
chromatography, at 10% ethyl acetate in hexanes for 4 column volumes (CV), 15-50% 
for 4CV, and then 50-75% for 4CV.  Four peaks were found, and NMR were taken of 
each.  The second peak was identified as the product of the aldehyde and oxazole 
complex.  Although there was an excess integration at ppm of 1.3, likely due to excess 
ethyl, the key protons around 4-5 that were seen in previous results exist in the correct 
ratio with the disubstituted benzene peaks. 1H NMR (appendix 12) (CDCl3) *. 7-8 (dd, 
C4H10AlCl	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4H, disubstituted benzene), 4-5 (s, 2H, H’s next to carbonyl), 1.3 (m, aliphatic 
hydrogens). The third, although the trace was broad, was likely the complex of the 
aldehyde and a hydrolyzed oxazole due to excess integration in the range of 3-4 pointing 
to an extra OH proton (appendix 13). 
Attempt at a reaction of ketone with oxazole in the presence of a dimethyl aluminum 
chloride catalyst.   
 
Six drops of the liquid N,N-Diethylacetoacetamide were added to the reaction 
vessel (82 mg, 0.002 mol) and dissolved in 2.5 mL toluene.  The reaction was placed 
stirring under nitrogen for 3 hours in a -84oC bath of ethyl acetate.  Six mL (0.0075 mol) 
of dimethyl aluminum chloride were added to the reaction mixture, let stir, and then 47.8 
mg (.002 mol) of oxazole in 2.5 mL of toluene was added to the reaction mixture.  The 
reaction was run under nitrogen gas for 38 hours while agitating.   
Purification was attempted with flash column chromatography at 20-75% ethyl 
acetate in hexanes for 20 column volumes.  Three peaks were visible, and NMR were 
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none was definitively the aldehyde or complexation peak.  It is likely that the separation 
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Appendix:  
 











Appendix 1: GC/MS of unpurified reaction of the synthesis of Methyl (2R)-3-benzyl-2-
methylpropionate. 
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Appendix 3: HNMR of 2R-3-benzyloxy-2-methylpropionic acid 
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Appendix 5: HNMR of N,N-Diethyl-3-hydroxy-2(R)-methylpropionamide 























Appendix 7: HNMR of N, N-Diethyl-2-(R)-methyl-3-oxopropionamide 
 












Appendix 8: GC/MS of 5-methoxy-2-methoxyphenyloxazole 
 
Appendix 9: HNMR of N,N-Diethylacetoacetamide 	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Appendix	  10:	  	  Peak	  1	  of	  	  ketone	  dimethyl	  aluminum	  chloride	  catalyst	  purification.	  	  	  	  
	  
Appendix	  11:	  Peak	  2	  of	  ketone	  dimethyl	  aluminum	  chloride	  catalyst	  purification.	  
	   45	  
  
Appendix 12: Peak 2 of diethyl aluminum chloride catalyst experiment 
 
Appendix 13:  Peak 3 of diethyl aluminum chloride catalyst experiment. 










Appendix 14: Potential hydrolyzed by-product of reaction with zinc chloride catalysis. 
 
Appendix 15: Unseparated product from second ZnCl2 Catalysis 	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